星奕昂创始人、董事长兼首席执行官王立群博士：中国科学技术大学细胞生物学学士、美国马里兰大学巴尔的摩分校分子生物学博士以及辛辛那提萨维尔大学工商硕士，美国国立健康研究院(NIH)博士后。

王立群博士在美国和中国的生物制药领域拥有丰富的专业技术和研发管理经验。在成立星奕昂之前，曾任复星医药副总、首席技术官和美国凯特合资公司复星凯特的总裁。用不到三年时间带领复星凯特完成了奕凯达的技术落地，注册临床和生产，成为获中国药监局批准上市的首个CAR-T产品。

王立群博士曾在美国宝洁、百时美施贵宝、阿斯利康以及葛兰素史克中国研发中心的重要管理岗位上任职近20年，参与和主导了多个新药的研发及转化工作。他在西比曼生物科技担任首席运营官期间，全面管理公司运营、细胞治疗产品的生产、药理和临床研究，并兼任干细胞事业部总经理。

Richard Liqun Wang Ph. D., MBA.

• Founder, Chairman and CEO， Neukio Biotherapeutics

• VP & CTO, Fosun Pharma

• Founding CEO of Fosun Kite Biotech, completed tech transfer, registration trial and market authorization application for Yescarta in China (the first CAR-T product) in less than three years

• COO of CBMG (Cellular Biomedical Group), managed production and clinical trials of stem cell and CAR-T therapies

• Head of Operations, GSK R&D Center in China

• Director of Alliance, Externalization and Portfolio Management, AstraZeneca Innovation Center China

• Associate Director, Discovery Portfolio and Project Management, Bristol-Myers Squibb USA

• Group Leader & Principal Scientist, Procter & Gamble Pharmaceuticals, USA

Richard received B.S degree in Cell Biology from the University of Science & Technology of China, Ph.D. in Molecular Biology from the University of Maryland, Baltimore and MBA from Xavier University, in Cincinnati. He obtained postdoctoral training at the National Institutes of Health, USA.